CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Secretaria da Saúde (São Paulo - Estado). Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Hemocentro de Ribeirão Preto (Institutional affiliation from the last research proposal) Birthplace: Brazil
Associate Professor, Division of Hematology, Hemotherapy, and Cell Therapy, Department of Medical Imaging, Hematology, and Clinical Oncology, University of São Paulo at Ribeirão Preto School of Medicine (FMRP-USP). Bachelor's degree in Medicine from the Federal University of Ceara (1999), with residency in Internal Medicine and Hematology/Hemotherapy at the University Hospital of FMRP-USP (2000-2003), Ph.D in Internal Medicine/Hematology at FMRP-USP (2008), and Post-Doctoral fellowship at Prof. Daniel G. Tenen laboratory at Harvard Medical School (2011-2013). Researcher and coordinator of the Master's Professional Program in Hemotherapy and Biotechnology at FMRP-USP and vice-coordinator of the Graduate Program in Clinical Oncology, Stem Cells and Cell Therapy. Experience in Internal Medicine with a focus on Hematology/Oncology, with emphasis on the following topics: etiopathogenesis, prognosis and treatment of myeloid neoplasms; phenotypic, molecular, and functional characterization of normal and neoplastic hematopoietic stem cells; and applications of molecular biology and flow cytometry for the study of hematopoietic neoplasms. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Despite advances in the diagnosis and treatment of acute myeloid leukemia (AML), the cure rate remains low even in patients with so-called favorable genetic characteristics and therapies that rarely include targeted drugs and bone marrow transplantation. Monitoring therapy response through measurable residual disease research helps predict outcomes, although clinical management for persis…
Background: Natural Killer (NK) cells, the major subset among innate lymphoid cells, can affect frequency and self-renewal of normal hematopoietic stem cells (Figueiredo-Pontes et al, Stem Cell Reports, 2021). In agreement, NK maturation and dysfunction may contribute to leukemogenesis in myeloproliferative neoplasms (Bianco & Arantes et al, Frontiers in Immunology, 2021) and Acute Myeloi…
Natural Killer (NK) cells, the major subset among Innate Lymphoid Cells (ILCs), can affect frequency and self-renewal of normal hematopoietic stem cells (Figueiredo-Pontes et al, Stem Cell Reports, 2021). On the other hand, NK maturation dysfunction may contribute to leukemogenesis in myeloproliferative neoplasms (Bianco & Arantes et al, submitted Frontiers in Oncology, 2021) and Acute My…
Considering that hematopoietic stem cells (HSC) directly respond to cytokines like IFNg, TNFa, TGFb, GM-CSF, MIP1, IL-10 and others, we hypothesized that Natural Killer (NK)-mediated cytokine production could regulate HSC function (subproject 1) and that its deregulation may favor malignant transformation (subproject 2). To address the role of NK function in normal hematopoiesis, we will …
Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by a malignant clonal disorder affecting the bone marrow due to the proliferation and expansion of leukemic stem cells (LSC) of the myeloid lineage. These cells undergo a blockage in their differentiation, impairing normal hematopoiesis and resulting in conditions such as anemia, granulocytopenia or thrombocytopenia. T…
Despite advances in the diagnosis and treatment of acute myeloid leukemia (AML), the cure rate remains low even in patients with so-called favorable genetic characteristics and therapies that rarely include targeted drugs and bone marrow transplantation. Monitoring therapy response through measurable residual disease research helps predict outcomes, although clinical management for persis…
In Chronic Myeloid Leukemia (CML) patients achieving sustained deep molecular response (DMR) with tyrosine kinase inhibitor (TKI) may discontinue treatment. Treatment-free remission (TFR) occurs in a minority without predictive biomarkers. T-cell (LT) and Natural Killer (NK)-mediated antitumor immunity may impact TFR maintenance. We aim to correlate LT and NK phenotypes with measurable re…
(Only some records are available in English at this moment)
Acute Myeloid Leukemia (AML) is a hematological disease characterized by a malignant clonal alteration that affects the bone marrow due to the proliferation and expansion of leukemia stem cells (LSCs) of myeloid lineage that undergo a blockage in their differentiation, thereby impairing normal hematopoiesis, resulting in cases of anemia, granulocytopenia, or thrombocytopenia. The prolifer…
Acute Myeloid Leukemia (AML) is a hematopoietic neoplasm of the myeloid lineage, characterized by the proliferation of myeloid blasts in the bone marrow, in the peripheral blood and/or in other tissues. The treatment of patients with AML depends on the definition of the disease subtype and on the prognostic risk stratification. The analysis of genetic and molecular abnormalities present a…
(Only some records are available in English at this moment)
Knowledge of the mechanisms underlying the normal development of blood cells will lead to new understanding of the pathogenesis of acute leukemias. Previous studies have demonstrated the role of the transcription factor abnormalities in acute myeloid leukemia (AML) in humans although this knowledge needs to be better translated into prognostic and therapeutic information. The major hypoth…
| 3 / 3 | Ongoing grants |
| 1 / 1 | Completed research grants |
| 6 / 6 | Ongoing scholarships in Brazil |
| 7 / 5 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 18 / 16 | All research grants and scholarships |
| Associated processes | |